Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia by Cristobal, I. (Ion) et al.
Acute Myeloid Leukemia Articles and Brief Reports
haematologica | 2012; 97(4) 543
Acknowledgements: this work 
was supported by the Ministerio
Educación y Ciencia (AP2006-
03038), Ministerio Ciencia 
e Innovación (PI081687),
Gobierno de Navarra
(14/2008), ISCIII-RTICC
(RD06/0020/0078), 
and FIMA y UTE (Spain). 
Manuscript received on
June 29, 2011. Revised
version arrived on October 13,
2011. Manuscript accepted 
on November 7, 2011.
Correspondence: 
María D. Odero, Division
of Oncology, Center for Applied
Medical Research (CIMA),
University of Navarra, Pio XII-55
31008 Pamplona, Spain. 
E-mail: modero@unav.es.
Phone: +34.948.194700. 
Fax: +34.948.194714.
The online version of this article
has a Supplementary Appendix.
Background
Protein phosphatase 2A is a novel potential therapeutic target in several types of chronic and
acute leukemia, and its inhibition is a common event in acute myeloid leukemia. Upregulation
of SET is essential to inhibit protein phosphatase 2A in chronic myeloid leukemia, but its
importance in acute myeloid leukemia has not yet been explored.
Design and Methods
We quantified SET expression by real time reverse transcriptase polymerase chain reaction in
214 acute myeloid leukemia patients at diagnosis. Western blot was performed in acute
myeloid leukemia cell lines and in 16 patients’ samples. We studied the effect of SET using cell
viability assays. Bioinformatics analysis of the SET promoter, chromatin immunoprecipitation,
and luciferase assays were performed to evaluate the transcriptional regulation of SET.
Results
SET overexpression was found in 60/214 patients, for a prevalence of 28%. Patients with SET
overexpression had worse overall survival (P<0.01) and event-free survival (P<0.01).
Deregulation of SET was confirmed by western blot in both cell lines and patients’ samples.
Functional analysis showed that SET promotes proliferation, and restores cell viability after pro-
tein phosphatase 2A overexpression. We identified EVI1 overexpression as a mechanism
involved in SET deregulation in acute myeloid leukemia cells.
Conclusions
These findings suggest that SET overexpression is a key mechanism in the inhibition of PP2A
in acute myeloid leukemia, and that EVI1 overexpression contributes to the deregulation of
SET. Furthermore, SET over-expression is associated with a poor outcome in acute myeloid
leukemia, and it can be used to identify a subgroup of patients who could benefit from future
treatments based on PP2A activators.
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ABSTRACT
Introduction
Identification of recurrent genetic alterations has provid-
ed novel targets to improve prognosis and treatment in
patients with acute myeloid leukemia (AML); however,
patients’ outcomes are still very poor.1 The protein SET
(I2PP2A/TAF-Iβ), a potent protein phosphatase 2A (PP2A)
inhibitor,2 has been implicated in many cell processes such
as DNA replication, chromatin remodeling, gene tran-
scription,3-4 differentiation,5 and migration,6 and cell-cycle
regulation.7 SET has been described as an oncogene that
regulates important signaling pathways.8 In fact, reported
SET functions include inhibiting the DNase activity of the
tumor suppressor NM23-H1, increasing AP-1 activity, acti-
vating MAPK signaling, or regulating granzyme B and
interferon-γ production in human NK cells.9-13 Moreover,
SET is overexpressed in several neoplasms,14 including
chronic myeloid leukemia (CML), in which it correlates
with the expression and activity of BCR/ABL, leading to
PP2A inhibition.15 PP2A is a tumor suppressor that regu-
lates a wide variety of signaling pathways,8,16-19 and its loss
of function has been associated with cell transformation.20-
21 PP2A has been described as a potential therapeutic target
in CML, Philadelphia-positive acute lymphoblastic
leukemia, and B-cell chronic lymphocytic leukemia.15,22-23
Our group has previously shown that SETBP1 protects
SET from protease cleavage in AML cells, leading to PP2A
inhibition.24 Moreover, we have recently reported that
PP2A inactivation is a recurrent event in AML, and that its
activation by forskolin reduces cell viability, and affects
AKT and ERK1/2 phosphorylation. In addition, we pro-
posed that SET overexpression could be a possible con-
tributing mechanism to PP2A inhibition in AML.25
In this study, we further investigated the importance of
SET deregulation in AML. We quantified SET in a series of
214 patients with AML at diagnosis, observing that SET
overexpression is a recurrent molecular event associated
with short overall survival. Analysis by western blot con-
firmed SET overexpression at the protein level in both
AML cell lines and patients’ samples. In addition, we
observed that SET promotes cell growth and restores the
reduced cell proliferation induced after PP2A overexpres-
sion. Furthermore, we identified EVI1 overexpression as a
mechanism contributing to SET deregulation in AML. The
high recurrence of this alteration indicates that SET over-
expression could represent a key inhibitory mechanism of
PP2A in AML cells, which could discriminate a subgroup
of patients who might benefit from future therapies with
PP2A activators.
Design and Methods
Cell cultures and transfection
EOL-1, HL-60, Kasumi-1, MV4-11, HEL, KG-1, KYO-1, MEG-
01 and K562 cells were maintained in RPMI-1640 (Invitrogen)
with 10% fetal bovine serum (FBS); NOMO-1 and KU-812 in
RPMI-1640 with 20% FBS; UT-7 in alpha-MEM (Invitrogen) with
20% FBS and 5 ng/mL GM-CSF; MUTZ-3 in 80% alpha-MEM
with 20% FBS and 10 ng/mL GM-CSF; and TF-1 in RPMI-1640
with 20% FBS and 10 ng/mL GM-CSF. Cell lines were grown at
37ºC in a 5% CO2 atmosphere. Media were supplemented with
penicillin G (100 U/mL), and streptomycin (0.1 mg/mL). Cells
were treated with the reagent forskolin (40 mM) (Calbiochem).
For transfection experiments we used the Nucleofector System
(solution V and protocol X-005 for HEL; solution R and protocol
V-01 for KG-1; solution V and protocol X-001 for TF-1) (Amaxa),
with 4 µg of plasmid vectors or 75 nM EVI1 siRNA D4 or D6
designed and synthesized by Dharmacon.
Patients’ samples
The study was based on bone marrow samples taken at diag-
nosis of AML from 214 patients. Clinical follow-up data were
available for 146 patients (72 men and 74 women; median age 59
years, range 19-82) (Online Supplementary Table S1). The median
overall survival of the whole cohort was 39.9 weeks (95% CI 29-
50.8) (Online Supplementary Figure S1). All patients included in the
overall survival analysis were treated with standard induction
chemotherapy based on anthracycline and cytarabine. High-dose
cytarabine and autologous or allogenic stem cell transplantation,
when possible, were used as consolidation therapy. Bone mar-
row samples from normal healthy donors were used as controls.
Samples were taken anonymously. The ethical committee and
institutional review board approved the project.
Plasmids
Human SET cDNA was obtained by reverse transcriptase poly-
merase chain reaction (RT-PCR) from K562 RNA using an
upstream primer containing an EcoRI site followed by the first 19
nucleotides of SET cDNA, and a downstream primer containing
the last 21 nucleotides of SET linked to a BamHI site. The
EcoRI/BamHI digested PCR product was subcloned into the
pEGFP-C2 vector leading to the pEGFPC2-SET construct. The
pCMV6-EVI1 construct was provided by Origene. All cloning
procedures were verified by sequencing.
Nucleic acid isolation and real time reverse 
transcriptase polymerase chain reaction
Total RNA was isolated using the RNeasy minikit (Qiagen).
cDNA was synthesized with SuperScriptIII Reverse
Transcriptase (Invitrogen). The expression of SETwas quantified
using a specific TaqMan Gene Expression Assay (Applied
Biosystems). GAPDHwas used as an internal control. Expression
levels of miR-199b were determined using a specific TaqMan
MicroRNA Assay (Applied Biosystems, USA), and U6B as the
internal control. For quantification of miR-199b, total RNA was
isolated using TRIzol Reagent (Invitrogen). Relative gene expres-
sion data were analyzed using the 2−ΔΔCT method,26 where ΔΔCT=
(CT,Target Gene - CT,GAPDH)Cell Line - (CT,Target Gene - CT,GAPDH)Normal Control. A gene was
considered deregulated if its expression value was higher or
lower than the cut-off value established for each gene
(mean+3SD), defined by the analysis of ten normal bone marrow
samples as previously described.25
Western blot analysis
Protein extracts were isolated using TRIzol Reagent
(Invitrogen) following the manufacturer’s indications, clarified
(12,000xg, 15 min, 4ºC), denatured and subjected to sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and western blotting. Antibodies used were mouse monoclonal
anti-β-actin (Sigma) and goat polyclonal anti-SET (Santa Cruz
Biotechnology). Proteins were detected with the appropriate sec-
ondary antibodies by chemiluminescence (ECL kit, GE
Healthcare).
Proliferation assay and cell viability
Cell proliferation was measured in triplicate wells by the MTS
assay in 96-well plates using the CellTiter 96 AQueous One
Solution Cell Proliferation Assay (Promega), following the manu-
facturer´s indications.
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Analysis of caspase-dependent apoptosis
The activity of caspase 3/7 was measured on untreated and
forskolin-treated cells using the caspase Glo-3/7 assay kit
(Promega Corp.) as previously described.25 Differences in cas-
pase-3/7 activity in forskolin-treated cells compared with
untreated cells are expressed as fold-change in luminescence.  
PP2A phosphatase activity assays
PP2A assays were performed with cell lysates (50 mg) using a
PP2A immunoprecipitation phosphatase assay kit (Millipore) as
previously described.24
Chromatin immunoprecipitation 
Real time RT-PCR (QRT-PCR) was performed on fragmented
chromatin precipitated by anti-EVI1 antibody or Normal Rabbit
IgG from the EVI1-positive TF1 cell line, and the EVI1-negative
MOLM13 cell line. Primers were designed to amplify the pro-
moter region of SET. Chromatin immunoprecipitation (ChIP)
was carried out using anti-EVI1, and IgG-isotype as a negative
control. The EVI1-positive target gene PBX1 was used as a posi-
tive control. Results were expressed as percentage of input as
calculated by QRT-PCR.
Bioinformatics analysis of the SET proximal promoter
We performed a bioinformatics analysis in order to identify
the presence of hypothetical binding-sites for transcription fac-
tors in the proximal promoter of the SET gene. The analysis
included a region containing 2,000 bp before the transcription
start site, and was carried out using the MatInspector (www.geno-
matix.de) program.
Statistical analysis
Statistical analyses were performed using SPSS 15 for Windows
(SPSS Inc, Chicago Illinois). Overall survival was defined as the
time from diagnosis to death from any cause or end of follow-up.
Disease-free survival was defined as the time from complete
remission until relapse or death. Event-free survival was defined as
the time from diagnosis until first event, in which failure to
achieve complete remission, relapse, death or end of follow-up
were considered events. Overall, disease-free and event-free sur-
vival were determined according to the Kaplan–Meier method;
survival comparisons were done with the log-rank test. A Cox
proportional hazards model was used to assess patients’ outcome
and was adjusted taking into consideration age, cytogenetic prog-
nostic group, complete remission, and SET overexpression. P val-
ues less than 0.05 were considered statistically significant.
Luciferase assay
Luciferase activity was measured using the Dual Luciferase
Assay kit (Promega) following the manufacturer´s instructions.
Firefly luciferase activity was normalized to Renilla luciferase
activity.
Results
Prevalence of SET overexpression in acute 
myeloid leukemia
To study the prevalence of SET overexpression and its
prognostic value in AML, we quantified the expression of
SET by QRT-PCR in a series of 214 patients with AML at
SET expression in AML
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Figure 1. SET is deregulated in samples from
patients with AML, and confers a poor outcome in
AML. (A) Kaplan-Meier analyses of overall survival
for SET overexpression in a series of 146 patients
with AML and clinical follow-up data available who
received induction therapy. (B) Kaplan-Meier analy-
ses of overall survival for SET overexpression in the
subgroup of patients with normal karyotype. (C)
Western blot analysis showing SET expression lev-
els in 16 AML patients at diagnosis.
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diagnosis. We next correlated SET overexpression with
cytogenetic and molecular markers, and studied the prog-
nostic relevance of this aberration. The patients’ character-
istics are presented in Table 1. SET was overexpressed in
28% of cases (60/214). The prevalence in the cytogenetic
prognostic groups was 24% (7/29) in the group with good
cytogenetics, 19.4% (21/108) in the group with intermedi-
ate cytogenetics, and 41.6% (32/77) in the group with
poor cytogenetics. Moreover, we found genetic aberra-
tions associated with SET overexpression: monosomy 7
(P<0.01), and overexpression of SETBP1 (P<0.01) and EVI1
(P=0.020) (Table 2).
Prognostic impact of SET overexpression 
in acute myeloid leukemia
Clinical follow-up data were available for 146 patients
who received induction therapy. The patients’ characteris-
tics are presented in Online Supplementary Table S1. As
expected, significant differences in overall survival accord-
ing to age, cytogenetic group, and complete remission rate
were found in this series (P<0.01) (Online Supplementary
Figure S1). In this cohort, we found that patients with SET
overexpression had significantly worse overall survival
(P<0.01) and event-free survival (P<0.01) (Figure 1 and
Online Supplementary Figure S2). There were no differences
in disease-free survival (P=0.229) (Online Supplementary
Figure S2). The prognostic impact of SET overexpression
was significant in patients younger (P=0.024) and older
(P<0.01) than 60 years (Online Supplementary Figure S3A).
In addition, SET overexpression had prognostic impact in
the subgroup of patients with normal karyotype (P<0.01)
(Figure 1 and Online Supplementary Figure S3B. Multivariate
I. Cristóbal et al.
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Table 1. Clinical and molecular characteristics at diagnosis of a series
of 214 patients with AML.
                                                                N. (%)
Sex                                                                                              
Male                                                                                  112       (53.8)
Female                                                                              96        (46.2)
No data                                                                               6               
Age
<60 years                                                                          99        (48.5)
>60 years                                                                         105       (51.5)
No data                                                                              10              
Complete remission
No                                                                                       51        (36.7)
Yes                                                                                     88        (63.3)
No data                                                                              75              
Diagnosis
AML-M0                                                                             19         (8.8)
AML-M1                                                                             42        (19.6)
AML-M2                                                                             47          (22)
AML-M3                                                                              7           (3.3)
AML-M4                                                                             35        (16.3)
AML-M5                                                                             37        (17.3)
AML-M6                                                                             14         (6.6)
AML-NOS                                                                          13         (6.1)
Secondary AML
No                                                                                      141         (81)
Yes                                                                                     33          (19)
No data                                                                              40              
Cytogenetic group
Good                                                                                  29        (13.6)
Intermediate                                                                  108       (50.4)
Poor                                                                                   77          (36)
SET overexpression                                                                                
No                                                                                      154         (72)
Yes                                                                                     60          (28)
SETBP1 overexpression                                                                         
No                                                                                      139       (72.4)
Yes                                                                                     53        (27.6)
No data                                                                              22              
EVI1 overexpression
No                                                                                      142       (77.6)
Yes                                                                                     41        (22.4)
No data                                                                              31              
FLT3-ITD
No                                                                                      116         (80)
Yes                                                                                     29          (20)
No data                                                                              69              
NPM1mutated
No                                                                                       22        (40.7)
Yes                                                                                     32        (59.3)
No data                                                                             160             
Table 2. Association between SET overexpression and clinical and genetic
parameters at diagnosis in 214 patients with AML. 
N. Cases        N. SET- (%)              N. SET+ (%) P
SET 214 154 (72) 60 (28)
Sex 208 149 59 0.319
Male 112 77 (68.7) 35 (31.3)
Female 96 72 (75) 24 (25)
Age 204 146 58 0.505
<60 years 99 73 (73.7) 26 (26.3)
≥ 60 years 105 73 (69.5) 32 (31.5)
Complete remission 139 102 37 0.571
No 51 36 (70.6) 15 (29.4)
Yes 88 66 (75) 22 (25)
Secondary AML 174 129 45 0.126
No 141 108 (76.6) 33 (23.4)
Yes 33 21 (63.6) 12 (36.4)
Prognostic group 214 154 60 0.004
Good 29 22 (76) 7 (24)
Intermediate 108 87 (80.6) 21 (19.4)
Poor 77 45 (58.4) 32 (41.6)
Cytogenetic group
Normal karyotype   yes 72 54 (56.2) 18 (43.8) 0.520
no 137 97 (70.8) 40 (29.2)
Trisomy 8                 yes 17 14 (82.3) 3 (17.7) 0.297
no 187 136 (72.7) 51 (27.3)
Monosomy 7          yes 31 16 (51.6) 15 (48.4) 0.006
no 166 123 (74) 43 (26)
SETBP1 overexpression 192 137 55 <0.001
No 139 109 (78.4) 30 (21.6)
Yes 53 28 (52.8) 25 (47.2)
EVI1 overexpression 183 137 46 0.020
No 142 112 (78.8) 30 (21.2)
Yes 41 25 (61) 16 (39)
FLT3-ITD 145 111 34 0.972
No 116 89 (76.7) 27 (23.3)
Yes 29 22 (75.8) 7 (24.2)
NPM1mutated and FLT3wt 38 31 7 0.341
No 17 15 (88.2) 2 (11.8)
Yes 21 16 (76.2) 5 (23.8)
analysis demonstrated that SET overexpression is an unfa-
vorable independent factor associated with overall sur-
vival in AML. 
Analysis of SET deregulation at the protein level 
in acute myeloid leukemia cells
To confirm these results at the protein level, we next
analyzed SET expression by western blot in 16 cases with
AML at diagnosis, for whom we had previous data about
PP2A status and expression.25 These patients’ characteris-
tics are included in Online Supplementary Table S2.
Western blot showed increased levels of SET protein in
nine out of the 16 cases (56.2%), and a good correlation
between SET mRNA and protein levels was observed
(Figure 1 and Online Supplementary Table S2). In addition,
western blot showed increased SET levels in AML cell
lines (Online Supplementary Figure S4). Protein extracts
from the CML cell lines K562, KYO-1, MEG-01 and KU-
812 were also tested. K562 was included as the positive
control for SET overexpression.15,24 Taken together, these
results indicate that SET overexpression is a common
event in AML.
SET induces proliferation in acute myeloid leukemia
cells and restores cell viability after PP2Ac 
overexpression
We had previously reported that PP2A inhibition is a
recurrent event in AML, and that PP2A activation decreas-
es the proliferation of AML cells.25 We, therefore, assessed
the effect of SET overexpression on cell growth by MTS
assay, observing an increased proliferation in HEL cells
transfected with SET, in comparison with cells transfected
with an empty vector (Figure 2A). Similar results were
observed in the KG-1 cell line (data not shown). In order to
analyze whether SET deregulation can alter the effect of
PP2A on cell growth, we next studied the effect of SET
overexpression after PP2A activation. SET overexpression
totally restored the proliferation in HEL cells ectopically
expressing the catalytic subunit PP2Ac (Figure 2B).
However, SET expression only partially restored prolifera-
tion after treatment with the PP2A activator forskolin
(Figure 2C), suggesting additional toxicity of this drug
independently of PP2A activation, as we have previously
observed.25
To further investigate the biological effect of SET over-
expression in AML, we assessed apoptosis with the cas-
pase Glo-3/7 assay kit in KG-1 cells ectopically expressing
SET, PP2Ac or both SET and PP2Ac. KG-1 cells transfected
with an empty vector were used as controls.
Overexpression of SET resulted in decreased caspase-
dependent apoptosis and, consistent with its ability to
decrease cell proliferation, transfection with PP2Ac had a
caspase-dependent pro-apoptotic effect (Online
Supplementary Figure S5). As a control we measured PP2A
activity and mRNA expression levels after transfection
with SET or PP2Ac (Online Supplementary Figure S6). The
findings indicate that caspase activation is a key step for
PP2A-mediated AML cell death and that SET overexpres-
sion inhibits PP2A, decreasing caspase-dependent apopto-
sis. Altogether, these results indicate that SET overexpres-
sion promotes cell viability and inhibits the effect of PP2A
in AML cells.
SET expression in AML
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Figure 2. SET induces cell growth and restores proliferation in
ectopically PP2A-expressing AML cells. (A) MTS assay show-
ing proliferation in HEL cells transfected with SET compared
to cells transfected with an empty vector; (B) MTS assay
showing proliferation in HEL cells transfected with PP2A
alone or in combination with SET or with an empty vector; (C)
MTS assay showing the effect of SET in cells treated with the
PP2A activator forskolin (40 mM). *P<0.05; ** P<0.01.
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Molecular mechanisms of SET deregulation 
in acute myeloid leukemia
We next investigated the molecular mechanisms
involved in SET deregulation in AML. In order to test
whether an altered expression of miR-199b, a recently
described SET regulator in choriocarcinoma,27 could be
deregulating SET in AML, we quantified miR-199b in 13
AML cell lines and in samples from 12 patients with AML
(9 with SET overexpression and 3 with normal SET levels).
None of the 13 AML cell lines analyzed showed miR-199b
downregulation (data not shown). However, we observed
downregulation of miR-199b in three out of nine samples
from AML patients with SET overexpression (data not
shown), suggesting that altered expression of miR-199b
could be deregulating SET in some AML patients.
The significant association between SET and EVI1 over-
expression in patients’ samples (P=0.02) led us to perform
a bioinformatics analysis of the SET proximal promoter
region. We identified hypothetical binding-sites for impor-
tant transcription factors such as AP-1, GATA1, and EVI1.
Analysis by western blot showed increased SET levels in
cells ectopically expressing EVI1, in comparison with non-
transfected cells or cells transfected with an empty vector
(Figure 3A). Moreover, chromatin immunoprecipitation
showed that EVI1 binds to the promoter region of SET
(Figure 3B). However, we detected no differences in the
luciferase assay (Figure 3C). In order to confirm the role of
EVI1 as a SET regulator we silenced EVI1 using two differ-
ent short interfering RNA (siRNA) specific for EVI1 and a
siRNA negative control as a reference. As expected, we
observed a decrease in SET levels at both protein and
mRNA levels in HEL (very high EVI1/very high SET) and
TF-1 (high EVI1/high SET) cells, whereas no changes were
observed in KG-1 cells (very low EVI1/normal SET)
(Online Supplementary Figures S7 and S8). Interestingly, we
observed increased PP2A activity in the HEL and TF-1 cells
with EVI1 silenced, probably as a consequence of the
decreased levels of the PP2A inhibitor SET (Online
Supplementary Figure S9). MTS assays were performed in
three cell lines previously used for EVI1 silencing (HEL,
KG-1 and TF-1), showing decreased proliferation of both
HEL and TF-1 cells after EVI1 suppression, which is con-
cordant with the decreased SET levels observed in these
cases (Online Supplementary Figure S10). We confirmed
these findings in AML patients’ samples at the protein
level. There was a high level of EVI1 protein in four out of
six AML cases with overexpression of SET; nevertheless,
EVI1 could not be detected in patients with no SET over-
expression (Figure 4). Altogether, these results indicate
that EVI1 overexpression could be a mechanism contribut-
ing to SET deregulation in AML.
Discussion
The SET protein is a potent PP2A inhibitor overex-
pressed in different human malignancies, including
BCR/ABL-positive leukemias.15 In fact, it has been demon-
strated that SET upregulation, and the resulting PP2A inhi-
bition, is critical for BCR/ABL-positive cells to fulfill their
tumorigenic potential.15 We report here that SET overex-
pression is a recurrent event that predicts adverse outcome
in AML patients. In addition, we have demonstrated that
SET induces cell growth, and restores the decreased prolif-
eration induced by PP2A overexpression. EVI1 overex-
pression was identified as an alteration involved in SET
deregulation in AML cells. Importantly, our data provide
evidence that SET overexpression could play an important
role as a key contributing mechanism involved in the
PP2A inhibition observed in AML.
We previously reported that PP2A inactivation is a recur-
rent event in AML.25 To evaluate the clinical relevance of
the endogenous PP2A inhibitor SET in AML, we assessed
I. Cristóbal et al.
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Figure 3. (A) Western blot
showing increased levels
of SET after transfection
with EVI1. (B) Specific
DNA binding of EVI1 to
the SET promoter was
detected by ChIP. Real
time PCR was performed
on fragmented chromatin
precipitated by anti-EVI1
antibody (gray bars) or
normal rabbit IgG (black
bars) from an EVI1-posi-
tive (EVI1+) TF1 cell line
and the EVI1-negative
(EVI1-) MOLM13 cell line.
Results are expressed as
percentage of input as
calculated by qRT-PCR.
The EVI1-positive target
gene PBX1 was used as a
positive control. (C)
Luciferase reporter assay
in HEK293 cells co-trans-
fected with pGL3-
SETpromoter and pCMV6-
EVI1 or an empty vector.
Firefly luciferase activity
was normalized to
Renilla luciferase activity.
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the prevalence and the prognostic significance of SET over-
expression in a large series of patients with AML at diagno-
sis, observing that it is a recurrent alteration (28%) that pre-
dicts adverse outcome (Figure 1). Interestingly, SET overex-
pression also had a prognostic impact in patients with a
normal karyotype (P<0.01), defining a subgroup of patients
with a worse outcome (Figure 1 and Online Supplementary
Figure S3B). Normal karyotype AML is the largest single
group of cytogenetically defined AML patients, represent-
ing more than 40% of cases of adult AML. This subgroup
has an intermediate risk prognosis, and although several
molecular aberrations that define good or poor prognosis
have been identified, the optimal post-remission therapy
remains poorly defined in these cases.28 It is, therefore,
important to identify genetic markers that could predict
prognosis in this subgroup of patients, as well as to develop
novel targeted therapies. 
Although multivariate analysis confirmed SET overex-
pression as an independent prognostic marker in our series,
SET overexpression was also associated with other adverse
prognostic markers, such as monosomy 7, SETBP1 overex-
pression, and EVI1 overexpression. These observations
suggest that SET deregulation could cooperate with other
additional aberrations in the leukemogenesis program.
Moreover, the high recurrence of SET overexpression indi-
cates that it could be playing a key role in the PP2A inhibi-
tion observed in AML cells, as described previously in
CML.15 Our group has recently reported that PP2A activa-
tion induces decreased proliferation in AML cells.25 We,
therefore, assessed the effect of SET on cell growth,
observing that it promotes proliferation, and impairs the
anti-proliferative role of PP2A in AML (Figure 2). However,
SET could have other effects apart from the inhibition of
PP2A since it has been reported to be an oncogene that reg-
ulates multiple cell processes and signaling pathways.2-13
Interestingly, SET itself has been recently described as a
new molecular target for cancer therapy. COG112, a novel
SET-interacting peptide, has shown promising effects in
glioblastoma and breast adenocarcinoma cell lines.29
The molecular mechanisms by which SET is deregulat-
ed in AML remain unknown. In a recent report, SET was
described as a target of miR-199b in human choriocarcino-
ma.27 We, therefore, hypothesized that downregulation of
this miRNA could be the key mechanism that deregulates
SET in AML. We found no association between the
expression of SET and miR-199b in 13 AML cell lines ana-
lyzed; however, QRT-PCR in nine AML patients with SET
overexpression showed downregulation of miRNA-199b
in three cases. These results indicate that an aberrant
expression of this miRNA could represent an alteration
contributing to SET overexpression in some AML patients.
However, studies including a larger number of AML
patients’ samples are required to determine the relevance
of miR-199b in SET deregulation. To investigate other
molecular events that could lead to SET overexpression in
AML cells, we performed a bioinformatics analysis of the
SET promoter, identifying hypothetical binding sites for
EVI1. The finding that SET and EVI1 overexpression were
significantly associated in our series (Table 2) led us to
investigate whether EVI1 could regulate SET at transcrip-
tional level. A chromatin immunoprecipitation assay and
functional studies showed that EVI1 positively regulates
SET; however, luciferase assays suggest that either EVI1
regulates SET indirectly or that its functional binding-site
is located in a different region of the SET promoter.
Although more studies are necessary to clarify the molec-
ular mechanism by which EVI1 regulates SET, our results
indicate that EVI1 overexpression could be an important
mechanism of SET deregulation in AML.
In conclusion, we show that SET overexpression is a
recurrent molecular event in AML. It promotes cell prolif-
eration, restores the reduced cell viability induced after
PP2A overexpression and is associated with a poor out-
come. Furthermore, EVI1 overexpression could be an
important mechanism that contributes to deregulating
SET in AML. SET overexpression is, therefore, a key
mechanism to inhibit PP2A in AML, and it could be a new
marker to identify a subgroup of patients with poor prog-
nosis who could be treated with PP2A activators in future
clinical trials.
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Figure 4. Western blot analysis showing EVI1 and
SET levels in 12 AML patients at diagnosis. A pro-
tein extract of the K562 cell line was used as the
positive control for SET and EVI1.
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